Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer

20 Aug 2024

Abstract excerpt

The CLDN18-ARHGAP fusion gene is an oncogenic driver newly discovered in gastric cancer. It was detected in 9% (8/87) of gastric cancer patients in our center. An immunogenic peptide specifically targeting CLDN18-ARHGAP fusion gene was generated to induce neoantigen-reactive T cells, which was proved to have specific and robust anti-tumor capacity both in in vitro coculture models and in vivo xenograft gastric...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Chronic Lymphocytic Leukemia Research
Share to Colorectal Cancer Treatments and Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39164472
DOI: 10.1038/s44321-024-00120-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancerPMID 39164472Read ↗

Car-γδ T Cells Targeting Claudin18.2 Show Superior Cytotoxicity Against Solid Tumor Compared to Traditional Car-αβ T CellsSemantic proximity Read ↗

Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for Gastric CancerSemantic proximity Read ↗

A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.Semantic proximity Read ↗

Enrichment of <i>CLDN18</i>‐<i>ARHGAP</i> fusion gene in gastric cancers in young adultsSemantic proximity Read ↗

Immunotherapy for gastric cancer: dilemmas and prospectSemantic proximity Read ↗

Claudin-18.2 expression is frequent in remnant gastric carcinoma and associated with microsatellite instability and Epstein-Barr viral infection phenotypes.Semantic proximity Read ↗

Pancreatic cancer–restricted cryptic antigens are targets for T cell recognitionSemantic proximity Read ↗

Exploring the therapeutic efficacy difference in claudin18.2-targeted cell therapy revealed by single-cell sequencingSemantic proximity Read ↗

Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody DevelopmentSemantic proximity Read ↗

A critical role of epithelial MHCII in initiation of autoimmune tumorigenesis and sustaining premalignancy growth in the stomachSemantic proximity Read ↗

Benefits of an immunogenic personalized neoantigen nanovaccine in patients with high-risk gastric/gastroesophageal junction cancerSemantic proximity Read ↗

Screening, Construction, and Preliminary Evaluation of CLDN18.2-Specific Peptides for Noninvasive Molecular ImagingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.